Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Nordic SME Sweden |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Attana has received its first order for the newly launched Attana Cell™ 250 instrument. The order has been placed from an existing pharma customer headquartered in Europe and is the result of several successful contract research projects initiated in the spring of 2018.
In March 2018, Attana announced the order of a smaller contract research project from a global pharma company. Following the success of several smaller research projects the customer has today placed an order for an Attana Cell™ 250 instrument. The order will affect the company's cashflow and earnings in Q4 2020 and Q1 2021.
"We are always happy to receive new orders, but we are particularly proud that this order comes from an existing contract research customer, validating our core offering. This illustrates what a small contract research project can lead to when we deliver high quality research and the customer appreciates the value of our technology and competence," comments Teodor Aastrup, CEO Attana.